The neurological disorder drug developer has secured $20m in a series B round backed by existing investors Johnson and Johnson and WuXi AppTec.
XW Laboratories, a China-based biopharmaceutical research and development company focused on neurological disorders, has raised $17.5m in series B financing from investors including pharmaceutical companies Johnson and Johnson and WuXi AppTec.
The round was co-led by Elements Capital and WI Harper, and included Kleiner Perkins Caufield & Byers (KPCB) China and KTB Network. The corporates participated through corporate venturing units Johnson and Johnson Innovation – JJDC and WuXi Ventures.
XW Laboratories is working on compounds based on specialised drug…
